# Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Study · id `cardio:ct-nct04848506` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04848506](<https://clinicaltrials.gov/study/NCT04848506>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04848506

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 900 participants.

## Technical summary

Registry record NCT04848506. Allocation not applicable; no masking; primary purpose treatment. Start 2021-05-06 (actual); primary completion 2029-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 900 participants (planned count; ClinicalTrials.gov record NCT04848506, source copy `cardio:ctgov-nct04848506-2026-10-13`, retrieved 2026-10-31)
- Started: 2021-05-06 (actual) (ClinicalTrials.gov record NCT04848506, source copy `cardio:ctgov-nct04848506-2026-10-13`, retrieved 2026-10-31)
- Primary completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT04848506, source copy `cardio:ctgov-nct04848506-2026-10-13`, retrieved 2026-10-31)
- Completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT04848506, source copy `cardio:ctgov-nct04848506-2026-10-13`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Brazil; Canada; Czechia; Denmark; France; Germany; Greece; Hungary; Iceland; Israel; Italy; Netherlands; Poland; Portugal; Spain; United Kingdom (ClinicalTrials.gov record NCT04848506, source copy `cardio:ctgov-nct04848506-2026-10-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04848506-2026-10-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
- Acronym: FOREST-HCM
- Condition: Symptomatic Hypertrophic Cardiomyopathy (HCM)
- Intervention (Drug): Aficamten (5 - 20 mg)
- Lead sponsor: Cytokinetics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Cytokinetics (`cardio:org-cytokinetics`)

## Provenance

Content hash: df6a85e83f0b7d4b3a9f921494736b695b719c30168063f5f53932950ea4be85
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
